InterOcean Capital Group’s AbbVie ABBV Stock Holding History

InterOcean Capital Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-200	Closed	-$32	–	427
2022 Q4	$32	Buy	+200	New	+$30.7K	﹤0.01%	417

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

InterOcean Capital Group's ABBV Position: Q1 2024 in Review

InterOcean Capital Group reduced its AbbVie (ABBV) stake by 0.28% in Q1 2024, selling an estimated $33.6K and leaving 68,921 shares worth $12.6M. The position accounts for 0.3% of the portfolio, ranked #76.

InterOcean Capital Group first reported a position in ABBV in Q4 2020 and has held it in 14 quarters since. 3,380 funds tracked by Wall St. Rank hold ABBV as of Q1 2024.

InterOcean Capital Group held 68,921 shares of AbbVie worth $12.6M as of Q1 2024.
InterOcean Capital Group sold 195 AbbVie shares in Q1 2024, an estimated $33.6K.
AbbVie made up 0.3% of InterOcean Capital Group's portfolio in Q1 2024, its #76 holding.
InterOcean Capital Group first reported a position in AbbVie in Q4 2020 and has held it in 14 quarters since.
3,380 funds tracked by Wall St. Rank held AbbVie as of Q1 2024.

Based on InterOcean Capital Group's 13F filing for Q1 2024, filed 13 May 2024.